Review in Journal of fungi (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed.
Journal of fungi (Basel, Switzerland) · 2026
Article
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Jayne Araújo da SilvaGraduate Program in Applied Microbiology and Parasitology, Biomedical Institute, Fluminense Federal University, Niteroi 24020-150, RJ, Brazil.ORCID 0000-0002-4341-8154
Adriany Lucas Dos SantosGraduate Program in Applied Microbiology and Parasitology, Biomedical Institute, Fluminense Federal University, Niteroi 24020-150, RJ, Brazil.ORCID 0009-0006-1352-6003
Júlia Andrade de Castro RodriguesCenter for Microorganisms' Investigation, Department of Microbiology and Parasitology, Biomedical Institute, Fluminense Federal University, Niteroi 24020-141, RJ, Brazil.
Mariana de Paula PiresCenter for Microorganisms' Investigation, Department of Microbiology and Parasitology, Biomedical Institute, Fluminense Federal University, Niteroi 24020-141, RJ, Brazil.
Marcelo Cerilo-FilhoGraduate Program in Applied Microbiology and Parasitology, Biomedical Institute, Fluminense Federal University, Niteroi 24020-150, RJ, Brazil.ORCID 0000-0002-4221-2728
Gil BenardLaboratory of Medical Mycology (LIM-53), Division of Clinical Dermatology, Institute of Tropical Medicine, Hospital das Clínicas, Faculty of Medicine, Universidade de São Paulo, São Paulo 05403-000, SP, Brazil.ORCID 0000-0002-5469-3602
José Rodrigo Santos SilvaGraduate Program in Biology of Infectious and Parasitic Agents, Centre for Biological and Health Sciences, Federal University of Sergipe, São Cristóvão 49100-000, SE, Brazil.ORCID 0000-0002-1918-7122
Ricardo Luiz Dantas MachadoGraduate Program in Applied Microbiology and Parasitology, Biomedical Institute, Fluminense Federal University, Niteroi 24020-150, RJ, Brazil.ORCID 0000-0002-8955-3204
Jéssica Dornelas da SilvaClinical Research Unit of the Antonio Pedro Hospital, NanoOnco 3D, Fluminense Federal University, Niteroi 24033-900, RJ, Brazil.
Héctor Manuel Mora-MontesDepartamento de Biología, División de Ciencias Naturales y Exactas, Campus Guanajuato, Universidad de Guanajuato, Noria Alta s/n, col. Noria Alta, Guanajuato 36050, Mexico.ORCID 0000-0001-6973-0595
Gutemberg Gomes AlvesCell and Molecular Biology Department, Institute of Biology, Fluminense Federal University, Niteroi 24210-201, RJ, Brazil.ORCID 0000-0003-0016-4809
Andréa Regina de Souza BaptistaGraduate Program in Applied Microbiology and Parasitology, Biomedical Institute, Fluminense Federal University, Niteroi 24020-150, RJ, Brazil.ORCID 0000-0002-0461-7521
Funding
Coordenação de Aperfeicoamento de Pessoal de Nível Superior Finance Code 001National Council for Scientific and Technological Development ARSB (308986/2022-9), RLDM (302722/2022-0), and GGA (307421/2022-8)
6 · The paper itself
Abstract
"Unusual sporotrichosis", a concept proposed in this review, refers to severe, extracutaneous, or anatomically atypical manifestations of sporotrichosis occurring in immunocompetent hosts and represents an underrecognized clinical subset associated with important diagnostic and therapeutic challenges. This systematic review aimed to characterize unusual sporotrichosis worldwide and to clarify its epidemiological, clinical, diagnostic, and therapeutic patterns. Following a registered protocol and PRISMA guidelines, PubMed, Scopus, and BVS/LILACS were searched up to November 2025 using a PICO-based strategy. Eligible studies included peer-reviewed case reports and case series with laboratory-confirmed sporotrichosis in patients without immunosuppression, diabetes mellitus, alcoholism, or other confounding comorbidities; classical lymphocutaneous and fixed cutaneous forms were excluded. From 922 records, 39 studies were included (13 case series and 26 case reports), yielding 55 cases reported between 1957 and 2024 across five world regions, mainly from the United States of America and Brazil. Adults aged 40-59 years (41.8%) and males (74.5%) predominated. Sapronotic transmission was most frequent (69.0%), although zoonotic transmission increased over time.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Unusual Sporotrichosis: A New Concept Proposal on the Unexpected Faces of · full record | OpenQuestion